COVID-19: What Do We Know About Outcomes in Hematologic Malignancies?
Patients with hematologic malignancies are at an advanced risk when they also have COVID-19. What have some recent studies suggested about outcomes in patients who have both?
Hematologic Cancers
Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Glofitamab Step-Up Dosing Efficacy Data Show High Complete Response Rates in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Researchers sought to determine whether glofitamab monotherapy would have high preliminary response rates in patients with R/R non-Hodgkin lymphoma.
Loncastuximab Tesirine Produces Durable Response in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether loncastuximab tesirine would have durable responses in heavily pretreated patients with R/R DLBCL.
Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Researchers Seek to Assess Monthly Adherence to Oral Chemotherapy Agents in Chronic Myeloid Leukemia
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...